LVTX
LAVA Therapeutics NV

966
Loading...
Loading...
News
all
press releases
LAVA Therapeutics GAAP EPS of -$0.24 beats by $0.18
LAVA Therapeutics GAAP EPS of -$0.24 beats by $0.18...
SeekingAlpha.com: All News·1y ago
News Placeholder
More News
News Placeholder
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone for EGFRd2...
Globe Newswire·1y ago
News Placeholder
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
PALM BEACH, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this...
Globe Newswire·2y ago
News Placeholder
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023UTRECHT, The Netherlands and PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX...
Globe Newswire·2y ago
News Placeholder
LAVA Therapeutics (NASDAQ:LVTX) Trading Up 37.7%
LAVA Therapeutics (NASDAQ:LVTX Get Free Report)s share price was up 37.7% during trading on Monday . The company traded as high as $3.72 and last traded at $3.03. Approximately...
Zolmax·2y ago
News Placeholder
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the...
Globe Newswire·2y ago

Latest LVTX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.